SensoLyte® Red Glucocerebrosidase (GBA) Activity Assay Kit Fluorimetric - 1 kit
- Cat.Number : AS-72259
- Manufacturer Ref. :
-
Availability :
In stock
- Shipping conditions : Ice fees will apply
Alternative choices
Glucocerebrosidase/GBA (also called acid β-glucosidase, Glucosylceramidase) is a lysosomal enzyme responsible for the breakdown of glucocerebroside releasing glucose and ceramide. Deficiency of this enzyme due to genetic mutations leads to accumulation of glucocerebroside and development of lysosomal storage disease, known as Gaucher disease (GD). Mutations in the glucocerebrosidase (GBA1) gene are also associated with increased risk for Parkinson disease and related disorders. It has been hypothesized that GBA, when not available to clear out proteins like alpha-synuclein, results in the accumulation of the proteins thereby contributing to Parkinson’s disease.
The SensoLyte® Red Glucocerebrosidase (GBA) Assay Kit detects GBA activity by using a highly sensitive fluorogenic substrate. The GBA substrate provided in the kit releases the red fluorescent dye resorufin upon Glucocerebrosidase cleavage with absorption/emission maxima at 570 nm/610 nm. This assay kit can be used to detect enzyme activity in purified enzyme preparations and compound screening. The Red Glucocerebrosidase (GBA) Assay is one-step homogenous reaction, which does not require the additional step of dispensing stop solution after the incubation, thereby suitable for HTS. The long wavelength fluorescence resorufin is also less interfered by the autofluorescence of components in biological samples and test compounds.
Specifications
Packaging | |
Kits components |
|
---|---|
Chemistry | |
UniProt number |
|
Properties | |
Absorbance (nm) |
|
Emission (nm) |
|
Storage & stability | |
Storage Conditions |
|
Activity | |
Application | |
Biomarker Target | |
Detection Method | |
Research Area | |
Sub-category Research Area | |
Usage |
|
Source | |
Host |
Downloads
You may also be interested in the following product(s)
References
Development of targeted therapies for Parkinson’s disease and related synucleinopathies
J Lipid Res . 2014 Oct 01 ; 55(10) 1996 | DOI : 10.1194/jlr.R047381
- E. Sybertz
- D. Krainc
Viable Mouse Models of Acid β-Glucosidase Deficiency: The Defect in Gaucher Disease
Am.J.Pathol . 2003 Nov 01 ; 163(5) 2093 | DOI : https://doi.org/10.1016/S0002-9440(10)63566-3
- Y.H. Xu
- et al
Multicenter Analysis of Glucocerebrosidase Mutations in Parkinson's Disease
N Engl J Med . 2009 Oct 22 ; 361 1651 | DOI : 10.1056/NEJMoa0901281
- E. Sidransky
- et al
Reduced glucocerebrosidase is associated with increased α-synuclein in sporadic Parkinson’s disease
Brain . 2014 Jan 28 ; 137(3) 834 | DOI : https://doi.org/10.1093/brain/awt367
- KE. Murphy
- et al